- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
ZIOPHARM Oncology is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a trailing 12-month revenue of around $398,000.
What's in this guide?
Our top picks for where to buy ZIOPHARM Oncology stock
- Trade $0 commission stocks, ETFs, and options with as little as $1
- After-hours trading available
- Earn 4.5% interest on uninvested cash with Gold
- 24/7 customer support
- $0 commission trading
- Instant withdrawals with a 1.75% fee
- Supports 250+ cryptocurrencies
- High-yield account earns up to 4.65% APY
Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.
How to buy ZIOPHARM Oncology stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ZIOP. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy ZIOPHARM Oncology stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
ZIOPHARM Oncology stock price (NASDAQ: ZIOP)
Use our graph to track the performance of ZIOP stocks over time.ZIOPHARM Oncology shares at a glance
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $1.07 |
200-day moving average | $1.89 |
Wall St. target price | $3.92 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.42 |
Is it a good time to buy ZIOPHARM Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ZIOPHARM Oncology financials
Revenue TTM | $398,000 |
---|---|
Gross profit TTM | $-52,696,000 |
Return on assets TTM | -39.32% |
Return on equity TTM | -84.01% |
Profit margin | 0% |
Book value | $0.32 |
Market Capitalization | $187.1 million |
TTM: trailing 12 months
ZIOPHARM Oncology share dividends
We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.
Have ZIOPHARM Oncology's shares ever split?
ZIOPHARM Oncology's shares were split on a 1:40 basis on 23 August 2005 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.
ZIOPHARM Oncology share price volatility
Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 1.6868. This would suggest that ZIOPHARM Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ZIOPHARM Oncology overview
ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.
Frequently asked questions
What percentage of ZIOPHARM Oncology is owned by insiders or institutions?Currently 9.927% of ZIOPHARM Oncology shares are held by insiders and 56.28% by institutions. How many people work for ZIOPHARM Oncology?
Latest data suggests 103 work at ZIOPHARM Oncology. When does the fiscal year end for ZIOPHARM Oncology?
ZIOPHARM Oncology's fiscal year ends in December. Where is ZIOPHARM Oncology based?
ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129 What is ZIOPHARM Oncology's ISIN number?
ZIOPHARM Oncology's international securities identification number is: US98973P1012 What is ZIOPHARM Oncology's CUSIP number?
ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101
More guides on Finder
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
9 Best Robo-Advisors for Automatic Investing
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Betterment alternatives
5 Betterment robo-advisor alternatives to consider when building your portfolio.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question